- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05683652
The Effect of Education and Telephone Follow-up Given to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-care Power
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The research consists of two parts. For the qualitative part of the research; A semi-structured interview form was created. In this form, face-to-face interviews were conducted with the patients receiving immunotherapy about the symptoms they experienced, how they coped, and the subjects they wanted to learn.
Quantitative part for sample selection; G Power 3.1 statistical program was used to calculate the sample size of the study. After calculating the effect size as 0.73 by using the standard deviation and group averages of the Self-Care Scale of the study closest to the research, the sample calculation was made (Çetin,2020). According to this; The sample size was calculated with a total of 56 patients, 28 people in both groups, with a power of 85% in the 95% confidence interval. However, due to the possible losses in the number of patients, 33 people were planned for both groups, with a total of 66 patients (Çetin A.A.2020).
A randomization list created with a computer-based random number sequence was used to ensure the random distribution of the patients scheduled for immunotherapy to the groups (www.random.org). The patients were numbered according to the order of arrival, and the patients were assigned to the groups (intervention group with training and followed up by phone, and control group with routine follow-up) according to the numbers in the randomization list. Due to the nature of the study, the principal investigator and patients could not be blinded during grouping. However, single-blind randomization was achieved by blinding the evaluator groups.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey
- Recruiting
- Ankara Medipol University
-
Contact:
- Lecturer
- Phone Number: 5077476389
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to read and write in Turkish,
- Absence of any psychiatric disorder that will reduce the ability to comprehend and understand,
- Not having any physical discomfort in the area of hearing or speaking that would prevent telephone conversations,
- Will receive immunotherapy for the first time and only,
- Willingness to participate in the research,
- Willingness to participate in the research,
- Patients who agreed to participate in the study verbally and in writing were included in the study.
Exclusion Criteria:
- Not being voluntarily or willing to participate in the research,
- Will receive radiotherapy or chemotherapy together with immunotherapy,
- Not knowing that he will receive immunotherapy,
- Patients who did not accept to participate in the study were not included in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nightingale Symptom Rating Scale
Time Frame: In patients receiving immunotherapy, the first measurements will be made at the end of the 1st cycle (the cycle is 28 days)
|
Nightingale Symptom Assessment Scale (N-SDS) is a quality of life scale developed by Gülbeyaz Can and Adnan Aydıner in 2009 for cancer patients.
Consisting of 38 items in total, the scale (N-CSS) has three sub-dimensions: Physical Well-Being (Physician) (items 1-4, 6-15, 23-27 and 37), Social Well-Being (SoIH) (5 and Articles 16-22) and Psychological Well-Being (PSYH) (Articles 28-36 and 38).
When each item in the scale is used alone, it can be reflected how the cancer patients who are planned to receive or receiving chemotherapy are affected by the disease/treatment-related problems.
In this Likert-type scale, the answer given by the patient to the evaluated item is scored as "0", if it is very little, "1", if it is a little, "2", if it is quite a lot, "3", and if it is too much, it is scored as "4".
A high score indicates that the level of being affected by the disease/treatment-related problems is high.
|
In patients receiving immunotherapy, the first measurements will be made at the end of the 1st cycle (the cycle is 28 days)
|
Demographic and Medical Characteristics - Patient Information Form
Time Frame: It will meet within 3 months with patients who agree to participate in the study.
|
It consists of a total of 8 questions created by the researcher after the literature review.
6 questions include medical characteristics, 2 questions include demographic characteristics.
|
It will meet within 3 months with patients who agree to participate in the study.
|
Telephone Interview Form
Time Frame: Patients in the experimental group receiving immunotherapy will be followed up by phone for 3 months.
|
atients who were given pre-immunotherapy training will be called after each cure and interviewed for symptom management.
A telephone interview form was created by the researcher to record the interviews.
|
Patients in the experimental group receiving immunotherapy will be followed up by phone for 3 months.
|
Phone Call Evaluation Form
Time Frame: It will be applied to the patients in the experimental group as a result of 3-month follow-up.
|
A phone call evaluation form prepared by the researcher will be used to evaluate the phone calls made after each cure.
It will be applied to the intervention group as a post-test.
|
It will be applied to the patients in the experimental group as a result of 3-month follow-up.
|
Self Care Power Scale
Time Frame: The first measurements of the patients receiving immunotherapy will be done at the end of the 1st cycle (each cycle is 28 days)
|
The scale used to measure an individual's self-care ability or self-care power was developed by Kearney and Fleicher (1979) in English with 43 items, and is a 35-item shortened Turkish form.
The scale focused on individuals' self-assessment of their involvement in self-care actions.
Each statement is scored from 0 to 4. Individuals' orientation towards self-care is determined by participants' responses on a 5-point Likert-type scale.
Among the answer options, "Doesn't describe me at all" is given 0 points, the others are given 1 point for "Doesn't describe me very well", 2 points for "I have no idea", 3 points for "Describes me a little", and 4 points for "Describes me a lot".In the Turkishized scale, 8 items (3, 6, 9, 13, 19, 22, 26 and 31) are evaluated as negative and the scoring is reversed.
The maximum score is 140.
The high score obtained from the scale indicates the high level of self-care or self-care ability and power of the individual.
There is no limit/cut off value.
|
The first measurements of the patients receiving immunotherapy will be done at the end of the 1st cycle (each cycle is 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nightingale Symptom Rating Scale
Time Frame: In patients receiving immunotherapy, the second measurements will be made at the end of the third cycle (the cycle is 28 days)
|
Nightingale Symptom Assessment Scale (N-SDS) is a quality of life scale developed by Gülbeyaz Can and Adnan Aydıner in 2009 for cancer patients.
Consisting of 38 items in total, the scale (N-CSS) has three sub-dimensions: Physical Well-Being (Physician) (items 1-4, 6-15, 23-27 and 37), Social Well-Being (SoIH) (5 and Articles 16-22) and Psychological Well-Being (PSYH) (Articles 28-36 and 38).
When each item in the scale is used alone, it can be reflected how the cancer patients who are planned to receive or receiving chemotherapy are affected by the disease/treatment-related problems.
In this Likert-type scale, the answer given by the patient to the evaluated item is scored as "0", if it is very little, "1", if it is a little, "2", if it is quite a lot, "3", and if it is too much, it is scored as "4".
A high score indicates that the level of being affected by the disease/treatment-related problems is high.
|
In patients receiving immunotherapy, the second measurements will be made at the end of the third cycle (the cycle is 28 days)
|
Self Care Power Scale
Time Frame: n patients receiving immunotherapy, the second measurements will be made at the end of the third cycle (the cycle is 28 days)
|
The scale used to measure an individual's self-care ability or self-care power was developed by Kearney and Fleicher (1979) in English with 43 items, and is a 35-item shortened Turkish form.
The scale focused on individuals' self-assessment of their involvement in self-care actions.
Each statement is scored from 0 to 4. Individuals' orientation towards self-care is determined by participants' responses on a 5-point Likert-type scale.
Among the answer options, "Doesn't describe me at all" is given 0 points, the others are given 1 point for "Doesn't describe me very well", 2 points for "I have no idea", 3 points for "Describes me a little", and 4 points for "Describes me a lot".In the Turkishized scale, 8 items (3, 6, 9, 13, 19, 22, 26 and 31) are evaluated as negative and the scoring is reversed.
The maximum score is 140.
The high score obtained from the scale indicates the high level of self-care or self-care ability and power of the individual.
There is no limit/cut off value.
|
n patients receiving immunotherapy, the second measurements will be made at the end of the third cycle (the cycle is 28 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- E-84892257-300-100327
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Self Care
-
Jewish General HospitalMcGill University; Canadian Institutes of Health Research (CIHR)CompletedSelf Care | Family CaregiversCanada
-
Akdeniz UniversityUnknownPeritoneal Dialysis | Self Efficacy | Perceived Social Support | Self-CareTurkey
-
University of VictoriaSwitch Research; Mathematics of Information Technology and Complex SystemsRecruitingMental Health | Self CareCanada
-
University of ChicagoActive, not recruitingConnecting Patients to Self-care ResourcesUnited States
-
University of the Western CapeUnknownSelf Efficacy | Self-Care
-
Duzce UniversityHacettepe UniversityNot yet recruitingMindfulness | Self-care | Laughter Yoga | Laughter Therapy
-
Namik Kemal UniversityCompletedSelf Care | Caregiver | Stoma Ileostomy | Stoma ColostomyTurkey
-
Nanyang Technological UniversityNational Gallery SingaporeEnrolling by invitationCompassion | Mental Health Wellness 1 | Self CareSingapore
-
Rutgers, The State University of New JerseyRecruitingSelf Efficacy | Emotion Regulation | Acceptability of Health CareUnited States
-
The University of Hong KongHospital Authority, Hong KongRecruitingHeart Failure | Self Care | Empowerment | Transitional Care | Disease ManagementHong Kong
Clinical Trials on TRAINING BOOKLET
-
Case Comprehensive Cancer CenterNot yet recruitingHead and Neck CancerUnited States
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)CompletedShift-Work Sleep DisorderUnited States
-
Nahid ZarifsanaieyCompletedLow Back PainIran, Islamic Republic of
-
University of California, San FranciscoNational Institute of Nursing Research (NINR)CompletedShift-Work Sleep DisorderUnited States
-
Pamukkale UniversityCompleted
-
Ankara Yildirim Beyazıt UniversityNot yet recruitingStress Urinary Incontinence
-
University of RostockDZNE, German Center for Neurodegenerative Disorders, GermanyUnknownDementia of the Alzheimer TypeGermany
-
University of Wisconsin, MadisonCompleted
-
Federal University of BahiaRecruitingAutism Spectrum DisorderBrazil
-
University of BolognaCompletedBehavior, Child | Dentist-Patient RelationsItaly